The incorporation of hydrophobic vitamin B12 derivatives into the single-compartment vesicles of N,N-didodecyl-Nα-[6-(tyimethylammonio)hexanoyl]-l-alaninamide bromide (N+C5Ala2C12) was found to be primarily concerned with the extent of insolubility of the cobalt complexes in the aqueous bulk phase, while such incorporation into the single-walled vesicles of N,N-ditetradecyl-Nα-[6-(trimethylammonio)hexanoyl]-l-histidinamide bromide (N+C5His2C14) was enhanced by the coordination interaction between the cobalt complex and the imidazolyl group of the lipid. In molecular aggregates formed with hexadecyltrimethylammonium bromide, α-[4-(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxypoly(oxyethylene), or N+C5Ala2C12, the alkylation rates of a hydrophobic vitamin B12 with 1-bromo-2-methylpropane and methyl 2-methyl-3-bromopropanoate were much enhanced relative to those in methanol. In the N+C5Ala2C12 vesicle, a two-step mechanism was observed for the alkylation with the latter reagent. The possible origin of such rate enhancement was discussed.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: